Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A
TCBP TC Biopharm	$0.68 -55.8%	$0.68	$0.50 ▼ $160.00	$279K	0.01	177,918 shs	5.33 million shs
TNFA TNF Pharmaceuticals	$0.09 +17.7%	$0.11	$0.06 ▼ $1.95	$1.30M	1.82	19.50 million shs	249.17 million shs
ZVSA ZyVersa Therapeutics	$0.12 -7.7%	$0.37	$0.11 ▼ $3.37	$953K	0.75	3.29 million shs	4,620 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NMTR 9 Meters Biopharma	0.00%	0.00%	-99.72%	-99.72%	-81.82%
TCBP TC Biopharm	0.00%	0.00%	0.00%	0.00%	-98.96%
TNFA TNF Pharmaceuticals	+13.72%	-17.74%	-33.30%	-54.84%	+7,789,900.00%
ZVSA ZyVersa Therapeutics	-3.49%	-13.33%	-51.85%	-77.22%	-95.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCBP TC Biopharm	1.4704 of 5 stars	3.5	0.0	0.0	0.0	0.6	0.8	0.6
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	0.5278 of 5 stars	0.0	4.0	0.0	0.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NMTR 9 Meters Biopharma	0.00	N/A	N/A	N/A
TCBP TC Biopharm	3.00	Buy	$48.00	6,948.46% Upside
TNFA TNF Pharmaceuticals	0.00	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
TCBP TC Biopharm	$4.76M	0.06	N/A	N/A	$519.58 per share	0.00
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	$0.36 per share	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
TCBP TC Biopharm	-$7.35M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	-$23.36M	-$2.31	N/A	∞	N/A	N/A	-69.21%	-33.98%	11/12/2025 (Estimated)
ZVSA ZyVersa Therapeutics	-$9.41M	N/A	0.00	N/A	N/A	N/A	-109.54%	-43.95%	11/13/2025 (Estimated)

Latest TCBP, TNFA, ZVSA, and NMTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	TNFA TNF Pharmaceuticals	N/A	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
TCBP TC Biopharm	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NMTR 9 Meters Biopharma	N/A	0.59	0.59
TCBP TC Biopharm	0.67	1.12	N/A
TNFA TNF Pharmaceuticals	N/A	0.93	0.93
ZVSA ZyVersa Therapeutics	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NMTR 9 Meters Biopharma	22.34%
TCBP TC Biopharm	16.25%
TNFA TNF Pharmaceuticals	9.64%
ZVSA ZyVersa Therapeutics	3.91%

Insider Ownership

Company	Insider Ownership
NMTR 9 Meters Biopharma	2.40%
TCBP TC Biopharm	15.44%
TNFA TNF Pharmaceuticals	0.45%
ZVSA ZyVersa Therapeutics	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
TCBP TC Biopharm	80	410,000	28,000	Not Optionable
TNFA TNF Pharmaceuticals	6	14.18 million	14.12 million	N/A
ZVSA ZyVersa Therapeutics	2	7.94 million	4.86 million	Not Optionable

TCBP, TNFA, ZVSA, and NMTR Headlines

Recent News About These Companies

ZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq Delisting

August 20, 2025 | msn.com

ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...

August 14, 2025 | bakersfield.comB

ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

August 14, 2025 | globenewswire.com

ZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product Development

August 13, 2025 | quiverquant.comQ

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

August 13, 2025 | globenewswire.com

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

July 21, 2025 | globenewswire.com

ZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading Thursday

July 16, 2025 | marketwatch.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | Morningstar

July 9, 2025 | morningstar.comM

ZyVersa’s VAR 200 approved for emergency use in rare kidney disease

July 9, 2025 | uk.investing.com

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - Nasdaq

July 9, 2025 | nasdaq.com

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

July 8, 2025 | benzinga.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | finanznachrichten.de

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis

July 8, 2025 | quiverquant.comQ

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediatorâ„¢Â VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - Nasdaq

June 27, 2025 | nasdaq.com

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...

June 26, 2025 | morningstar.comM

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...

June 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCBP, TNFA, ZVSA, and NMTR Company Descriptions

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

TC Biopharm NASDAQ:TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TNF Pharmaceuticals NASDAQ:TNFA

$0.09 +0.01 (+17.72%)

As of 11:29 AM Eastern

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

ZyVersa Therapeutics NASDAQ:ZVSA

$0.12 -0.01 (-7.69%)

As of 10:36 AM Eastern

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time